Quick Links

Dietary n-3 fatty acid effects on neutrophil lipid composition and mediator production. Influence of duration and dosage.

Authors: F H Chilton|||M Patel|||A N Fonteh|||W C Hubbard|||M Triggiani

Journal: The Journal of clinical investigation

Publication Type: Journal Article

Date: 1993

DOI: PMC330004

ID: 8380809

Affiliations:

Affiliations

    Department of Medicine, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27157.||||||||||||

Abstract

Healthy volunteers supplemented their usual Western diets with Promega fish oil supplement (eicosapentaenoic acid [EPA], 0.28 g; docosahexaenoic acid [DCHA], 0.12 g; other n-3 fatty acids 0.10 g per capsule) using three protocols. Initial experiments (protocol 1 and 2) investigated the kinetics of incorporation of n-3 fatty acids into serum and neutrophil lipids after 10 capsules/d of Promega. EPA was rapidly detected in both serum and neutrophil lipids; the arachidonic acid (AA) to EPA ratio in neutrophil phospholipids showed a maximal reduction of 49:1 to 8:1 within 1 wk of beginning supplementation. EPA was preferentially incorporated into phosphatidyl-ethanolamine and phosphatidylcholine but not phosphatidylinositol. Long-term supplementation for up to 7 wk did not influence the AA/EPA ratio or the distribution of EPA among neutrophil phospholipids in a manner that was not observed after the first week. Neutrophils produced similar quantities of platelet-activating factor and slightly lower quantities of leukotriene B4 during long-term supplementation when compared with presupplementation values. Experiments examining the influence of Promega dosage indicated that the AA/EPA ratio in neutrophil lipids decreased in a dose-dependent manner. Only when the dose was increased to 15 capsules/d was there a reduction in the AA/DCHA ratio in neutrophil lipids. The quantity of AA in neutrophil lipids remained relatively constant at all supplement doses. Taken together, the current study demonstrates the capacity of n-3 fatty acids provided with a Western diet to be rapidly incorporated into neutrophil lipids. However, dietary n-3 fatty acids appear not to significantly reduce arachidonate content within neutrophil phospholipids. Constant arachidonate levels may account for the lack of large reductions in the biosynthesis of lipid mediators by neutrophils after fish-oil supplementation.


Chemical List

    Dietary Fats|||Fatty Acids|||Fatty Acids, Omega-3|||Fish Oils|||Lipids|||Phospholipids|||Platelet Activating Factor|||Leukotriene B4|||Promega|||leukotriene B5|||Eicosapentaenoic Acid

Reference List

    Lancet. 1978 Jul 15;2(8081):117-9|||Ann Allergy. 1989 Jun;62(6):534-7|||J Lipid Res. 1982 Jan;23(1):190-6|||Scand J Clin Lab Invest Suppl. 1982;161:7-13|||J Biol Chem. 1983 Jun 25;258(12):7268-71|||Biochem Biophys Res Commun. 1983 Nov 30;117(1):282-8|||J Biol Chem. 1984 Feb 25;259(4):2383-9|||Prostaglandins. 1984 Feb;27(2):217-32|||Biochem Biophys Res Commun. 1984 May 16;120(3):907-18|||J Biol Chem. 1984 Jun 25;259(12):7615-21|||J Biol Chem. 1984 Oct 10;259(19):12014-9|||Lipids. 1984 Aug;19(8):617-24|||J Immunol. 1985 Mar;134(3):1914-9|||Biochim Biophys Acta. 1986 Feb 12;875(2):382-91|||Am J Clin Nutr. 1986 Apr;43(4):566-98|||Lipids. 1989 Jun;24(6):477-81|||J Lipid Res. 1989 Dec;30(12):1977-81|||Circulation. 1990 Jul;82(1):178-87|||Circulation. 1990 Aug;82(2):428-38|||J Immunol. 1990 Oct 1;145(7):2241-8|||J Biol Chem. 1990 Oct 25;265(30):18059-62|||J Immunol. 1991 Jul 1;147(1):231-6|||World Rev Nutr Diet. 1991;66:367-82|||Am J Clin Nutr. 1991 Jul;54(1):111-7|||J Immunol. 1991 Jul 15;147(2):621-6|||Lipids. 1991 Dec;26(12):1223-6|||Can J Biochem Physiol. 1959 Aug;37(8):911-7|||Lancet. 1985 Jan 26;1(8422):184-7|||Clin Sci (Lond). 1985 Apr;68(4):449-54|||Proc Natl Acad Sci U S A. 1985 Mar;82(5):1540-3|||N Engl J Med. 1985 May 9;312(19):1217-24|||J Lipid Res. 1985 Apr;26(4):457-64|||J Exp Med. 1985 Oct 1;162(4):1336-49|||J Clin Invest. 1985 Oct;76(4):1626-31|||J Clin Invest. 1981 Aug;68(2):556-9|||Biomed Environ Mass Spectrom. 1986 Mar;13(3):107-11|||J Biol Chem. 1986 Jun 15;261(17):7592-5|||Prostaglandins Leukot Med. 1986 Aug;23(2-3):135-40|||J Clin Immunol. 1986 Sep;6(5):402-10|||Arthritis Rheum. 1987 Sep;30(9):988-97|||Lipids. 1987 Oct;22(10):744-50|||Thorax. 1988 Feb;43(2):84-92|||J Lipid Res. 1989 Jan;30(1):77-87|||Am Rev Respir Dis. 1989 Jun;139(6):1395-400|||J Clin Invest. 1985 Dec;76(6):2446-50